Risankizumab (Skyrizi, AbbVie) is indicated 'for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

If people with the condition and their clinicians consider risankizumab to be 1 of a range of suitable treatments (including ustekinumab), after discussing the advantages and disadvantages of all the ...

There is a simple discount patient access scheme for risankizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact pricing@abbvie ...

Lecanemab (also called Leqembi and made by Eisai) is for slowing progression in mild cognitive impairment or mild dementia due to Alzheimer’s disease (AD) in adults and has been licensed by The ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Review and download supporting evidence. Includes the full guideline if available.

This topic was considered by the chair and vice chair of NICE's highly specialised technologies evaluation committee. Committee members are asked to declare any interests in the technology being ...

Tools to help you put the guidance into practice.

Risankizumab (Skyrizi) is available on the NHS as a possible treatment for moderately to severely active ulcerative colitis in adults when: conventional or biological treatment cannot be tolerated, or ...